Validation of the personalized sarcoma care prognostic tool in Turkish patients with soft tissue sarcomas

Objective: To validate the personalized sarcoma care (PERSARC) tool for predicting overall survival (OS) in a cohort of Turkish patients with soft tissue sarcomas (STS) and to assess its accuracy and clinical utility in a non-Western population.

Methods: A retrospective analysis was performed on 100 patients diagnosed with STS between 2017 and 2023. Demographic, clinical, pathological, and treatment-related data were collected. Personalized sarcoma care predictions for OS and disease-free survival were compared with actual outcomes using calibration plots. Predictive performance was evaluated using receiver-operating characteristic analysis and Cox regression models.

Results: Of the 100 patients, 59% were male and 57% were older than 50 years. Most tumors were deep-seated (75%) and >10 cm in size (52%). High-grade (Grade 3) tumors were present in 59% of cases. R0 resection was achieved in 95%, with neoadjuvant and adjuvant radiotherapy administered in 46% and 34% of patients, respectively. Local recurrence occurred in 14%, and distant metastases in 27%. At 3-year follow-up, 72% were alive. Personalized sarcoma care predicted 5-year OS as ≤50% in 33%, 51%-75% in 35%, and >75% in 32% of patients. Receiver-operating characteristic analysis demonstrated high predictive performance (area under the curve = 0.844; accuracy = 0.848; sensitivity = 0.607; specificity = 0.944). Personalized sarcoma care score was significantly associated with survival (P < .001), with a C-index of 0.857 (95% CI: 0.769-0.947).

Conclusion: The PERSARC model demonstrates high predictive accuracy and calibration for Turkish STS patients, supporting its generalizability beyond Western populations. It offers a robust tool for personalized prognostication in clinical sarcoma care. Prospective validation in larger, diverse cohorts is recommended.

Cite this article as: Kanay E, Bulut HI, Demiroz S, et al. Validation of the personalized sarcoma care prognostic tool in Turkish patients with soft tissue sarcomas. Acta Orthop Traumatol Turc., 2026, 60(3), 0583, doi: 10.5152/j.aott.2026.25583.